Hard to believe its gotten this 'cheap' now...
At some point, they will give enough data to the fda,
be able to PROVE the testing has some level of
ACCURACY. At least enough to be able to be confirmed
for some degree of drug testing acceptable for the ones
using it.
I doubt it will ever replace the urinalysis testing for high end
security related positions (I did a few of these over my career,
just the threat of a 'random' test is what kept many who wanted
to keep their jobs 'in-line' if you get my drift.
So the question is, how big a % of those that need periodic/random
testing will this be deemed 'acceptable' for. With the bigger question being,
can it cover the DRUGS of concern. Cause if for instance, it can't detect
something like meth, or synthetics and those that are subject to possibly being
tested finding this out?
Disclaimer: don't own any myself at this point, but been following it because
someone else bought shares at a 'much' higher price. And the reason I didn't buy
into it was I didn't like that they tried to get by with as little trial data, didn't like the
'accuracy' claim that 95% (if I got the number right) was 'good enough'.
So told this individual they would be doing more trials and why. So now the
question is, will their 'accuracy' claim and 'range of detection' be good enough
to get approved for at least 'some' sector of the population??
But at least the share price is now so cheap? But even now, buy a few thousand
shares and one could see that still wiped out. Hmmm to buy or not to buy, that
is the question.. But on the plus side, maybe getting their heads handed to them a
couple of times by the fda finally made them realize trying to 'get by' was not the
right approach to take.
AI
Market Data 
Markets 
